Navigation Links
Genomma Lab Announces Updated Fourth Quarter 2008 Guidance
Date:1/13/2009

MEXICO CITY, Jan. 13 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company") announces that based on the main preliminary indicators obtained at the close of the fourth quarter of 2008, the Company expects to report slightly lower results than the original growth expectations. However, product sales at the point of sale continue to be in line with original projections.

Despite favorable acceptance at the point of sale, some of Genomma Lab's clients chose to marginally reduce inventory levels during the last two weeks of December, in light of the current economic situation.

During the fourth quarter, the Company maintained a strict focus on working capital, placing the Company in a very solid position in terms of liquidity.

Genomma Lab will report fourth quarter results on February 17, 2009, followed by the quarterly conference call, which will take place on the following day.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is a leading over-the-counter pharmaceuticals and personal care products company in Mexico with international presence. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share.

Genomma Lab's shares trade on the Mexican Stock Exchange under the ticker symbol "LAB".

    Web Site: www.genommalab.com

    Investor Relations Contact:
    Tel: +52 (55) 5081 0000 Ext. 4250
    E-mail: inversion@genommalab.com

    In New York:
    i-advize Corporate Communications, Inc.
    Tel: (212) 406-3691/95
    E-mail: genomma@i-advize.com

'/>"/>
SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Genomma Lab, New Participant in Market-Maker Program
2. Genomma Lab Announces Initiation of Stock Repurchase Fund
3. Genomma Lab Announces the Successful Launch of the Ma Evans Brand
4. Genomma Lab Announces 2009 Earnings Guidance
5. Genomma Lab Internacional Acquires UNIGASTROZOL
6. Webcast Alert: Genomma Lab Internacional, S.A.B. de C.V. announces Second Quarter 2008 Results Conference Call
7. Genomma Lab Prices Initial Public Offering and Begins Trading on Mexican Stock Exchange
8. American Journal of Nursing announces 2008 Book of the Year Awards
9. AllMed Announces PeerScore Solutions for Hospital Peer Review
10. ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd.
11. Nationwide Medical/Surgical Announces They Will Carry Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 Getting breast implants is ... completely optional or due to medical necessity. Either way, women ... to prepare for it, says Robert Kraft, MD, Plastic Surgeon ... implant removal surgeries are performed each year in the United ... 70 percent of those procedures stem from three main problems: ...
(Date:7/22/2014)... Southlake, TX (PRWEB) July 22, 2014 ... proving to address skin laxity with results that are ... opposed to topically treating the skin with radio frequency, ... probes which are inserted under the skin to “inject” ... studies have shown that this single treatment solution for ...
(Date:7/21/2014)... (PRWEB) July 22, 2014 On Monday, September ... Charity Golf Outing honoring Mike McGuriman-Motorola Solutions at The Knoll ... outing begins with registration and lunch at 11 a.m. ... and prizes. Price increases to $250 after September 7th. ... for $100 per person. The dinner will include a ...
(Date:7/21/2014)... (PRWEB) July 21, 2014 PowerObjects, ... service, support, education, and add-ons for Microsoft Dynamics ... Inner Circle, an elite group of the most ... with sales achievements that rank them in the ... of partners. Members of the Microsoft Dynamics Inner ...
(Date:7/21/2014)... human nature to hate losing. , Unfortunately, it,s ... abandoning a solid strategy and thus increasing your chances ... conclusion of a Brigham Young University study published this ... finding is based on an analysis of two decades ... focused on whether coaches adjusted their personnel following games ...
Breaking Medicine News(10 mins):Health News:Is Breast Implant Removal Right for You? Plastic Surgeon Dr. Robert Kraft With Advanced Dermatology, PC Explains Breast Implant Removal and Offers Tips On Procedure 2Health News:Is Breast Implant Removal Right for You? Plastic Surgeon Dr. Robert Kraft With Advanced Dermatology, PC Explains Breast Implant Removal and Offers Tips On Procedure 3Health News:New Minimally Invasive Procedure, ThermiTight, “Injects” Radio Frequency to Treat Skin Laxity 2Health News:7th Annual Push to Walk Golf Outing to Be Held September 22nd 2Health News:PowerObjects Joins the 2014 Microsoft Dynamics Inner Circle 2Health News:'Moral victories' might spare you from losing again 2
... HealthDay Reporter , TUESDAY, May 17 (HealthDay News) ... birth defects in women taking these drugs during the first ... the drugs are relatively new, further studies are needed to ... In a large study of children born in Denmark, ...
... City, the prevalence of asthma among children entering school ... children growing up within walking distance of each other ... asthma. In the first comprehensive effort to understand ... Mailman School of Public Health compared the household presence ...
... . , Pediatric and young adult leukemia and ... the Cole Foundation,s announcement that it would provide more than ... four McGill University young scientists. "The Cole Foundation is dedicated ... the age of 25, and the research projects we finance ...
... from Boston University School of Medicine (BUSM) have discovered ... syndromes. The team connected pharmacological properties of the Novartis ... for the first time after investigating adverse reactions suffered ... treatment of osteoporosis. These findings appear online in the ...
... -- A gene variation that causes faulty cholesterol regulation also ... may be a reason why some women can,t get pregnant, ... more than 200 infertile women who were undergoing in vitro ... the scavenger receptor class B type 1 (SCARB1) gene. ...
... the intermittent interruption of breathing that occurs in patients with ... cells and increased tumor growth in mice, according to researchers ... mouse models tended to contain more dead cells, indicating a ... the study will be presented at the ATS 2011 International ...
Cached Medicine News:Health News:Newer Epilepsy Meds Less Likely to Cause Birth Defects: Study 2Health News:Newer Epilepsy Meds Less Likely to Cause Birth Defects: Study 3Health News:Cockroach allergens in homes associated with prevalence of childhood asthma in some neighborhoods 2Health News:Cole Foundation injects $700,000 into childhood cancer research 2Health News:Gene Variation May Explain Some Female Infertility Cases 2Health News:Obstructive sleep apnea linked to cancer growth in mice 2Health News:Obstructive sleep apnea linked to cancer growth in mice 3
(Date:7/21/2014)... LA JOLLA, Calif. , July 21, 2014 ... RGLS ), a biopharmaceutical company leading the discovery ... today that the U.S. Food & Drug Administration ... a single stranded, chemically modified oligonucleotide that binds ... as a therapeutic for the treatment of Alport ...
(Date:7/21/2014)... , July 21, 2014  Valeant Pharmaceuticals ... (TSX: VRX) has contacted both the Autorite des ... and the U.S. Securities and Exchange Commission ... ) apparent attempt to mislead investors and manipulate ... to make false and misleading statements regarding Valeant,s ...
(Date:7/21/2014)... , July 21, 2014  CASI Pharmaceuticals, Inc. (Nasdaq: ... therapeutics for the treatment of cancer and other diseases, ... and Drug Administration (CFDA) has approved the Company,s application ... breast cancer (TNBC) patients in China ... Ken K. Ren , Ph.D., CASI,s Chief ...
Breaking Medicine Technology:Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 2Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 3Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 4Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 5Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 6Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 7CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 2CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 3CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 4
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
...
...
Medicine Products: